Orchestra BioMed Holdings (OBIO) Net Income towards Common Stockholders Growth (3y) (2024 - 2026)
Orchestra BioMed Holdings (OBIO) Net Income towards Common Stockholders Growth (3y) (2024 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.30% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 71.02% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 37.89% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.99% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -38.56% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 37.44% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 62.15% |
| 10 | Orchestra BioMed Holdings | 265.06 Mn | 80.63 Mn | 63,000.00 | -12.40% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -12.40% |
| Mar 31, 2026 | -20.19% |
| Dec 31, 2025 | 38.10% |
| Sep 30, 2025 | -25.24% |
| Jun 30, 2025 | -39.82% |
| Mar 31, 2025 | -51.78% |
| Dec 31, 2024 | -409.04% |
| Sep 30, 2024 | -421.23% |
| Jun 30, 2024 | -484.22% |
| Mar 31, 2024 | -429.29% |